Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer


Bayoglu I. V. , Yildiz İ. , Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., ...More

JOURNAL OF BUON, vol.20, no.2, pp.460-467, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2015
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.460-467

Abstract

Purpose: Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (rnFOLFOX6) or capecitabine/oxaliplatin (XELOX).